Naringenin trimethyl ether

CAS No. 38302-15-7

Naringenin trimethyl ether( —— )

Catalog No. M18499 CAS No. 38302-15-7

Naringenin trimethyl ether shows significant molluscicidal activity with a median lethal concentration (LC(5)) of 3.9 μg/mL.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 37 In Stock
5MG 33 In Stock
10MG 59 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Naringenin trimethyl ether
  • Note
    Research use only, not for human use.
  • Brief Description
    Naringenin trimethyl ether shows significant molluscicidal activity with a median lethal concentration (LC(5)) of 3.9 μg/mL.
  • Description
    Naringenin trimethyl ether shows significant molluscicidal activity with a median lethal concentration (LC(5)) of 3.9 μg/mL.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    38302-15-7
  • Formula Weight
    314.33
  • Molecular Formula
    C18H18O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COC1=CC=C(C=C1)C2CC(=O)C3=C(C=C(C=C3O2)OC)OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Tetrahydropalmatine

    Tetrahydropalmatine, an active component isolated from corydalis (a Chinese herbal medicine), possesses analgesic effects.

  • Brentuximab vedotin

    Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.

  • S107

    S107 is a RyR-selective 1, 4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.